My three top picks are CRISPR Therapeutics (NASDAQ: CRSP), DraftKings (NASDAQ: DKNG), and Roivant Sciences (NASDAQ: ROIV). This leading gene-editing company sports a broad pipeline of candidates that could bend the curve on several hard-to-treat ailments such as diabetes, a variety of blood cancers, and scores of rare diseases. The secret ingredient in DraftKings' apparently irresistible gumbo is its ability to continually grow revenue, even in an environment characterized by sky-high interest rates and sticky inflation.